Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in ...

Scientists at the 2026 ACTRIMS forum meet to assess current approaches and explore new directions for MS research and care.

For years, researchers have been hopeful they could get under the hood of multiple sclerosis. The neurological condition shows up in over 2.5 million people around the world, but it doesn’t always ...

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

Multiple sclerosis (MS) is primarily recognised as a chronic demyelinating disease of the central nervous system, yet its impact extends to the autonomic nervous system (ANS), which governs vital ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

Appealing an insurance claim denial with multiple sclerosis often requires following the rules and being persistent.

A new study reveals how Epstein-Barr virus may provoke immune cells to attack the brain, offering fresh hope for treating ...

Biogen topped fourth-quarter expectations Friday, thanks to far better-than-expected sales of multiple sclerosis treatment ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks BioNxt Solutions has made significant ...